Medicinova announced the phase 1B/2a clinical trial data of Mn-166 (ibudilast) for glioblastoma patients at the American Society of Clinical Oncology (ASCO) Annual Meeting in the United States in 2024.
美第奇新星生物技术宣布在2024年美国临床肿瘤学会（Asco）年会上公布了Mn-166（伊布地那）用于胶质母细胞瘤患者的1B/2a期临床试验数据。
Medicinova announced at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting the phase 1B/2a clinical trial data of Mn-166 (ibudilast) for patients with glioblastoma in the United States.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.